Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 20/20 | 0.64 |
| ▸ | GSK3A | P49840 | 19/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | PIM1 | P11309 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 1/20 | 0.52 |
| ▸ | TYK2 | P29597 | 1/20 | 0.52 |
| ▸ | SYK | P43405 | 1/20 | 0.52 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.52 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.52 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20205089 | 0.95 | GSK3B (0.62) | GSK3BGSK3AMAPTJAK2PIM1 | |
| SCHEMBL29939473 | 0.95 | GSK3B (0.62) | GSK3BGSK3AMAPTJAK2PIM1 | |
| SCHEMBL20205027 | 0.94 | GSK3B (0.67) | GSK3BGSK3AMAPTJAK2PIM1 | |
| SCHEMBL29939275 | 0.94 | GSK3B (0.67) | GSK3BGSK3AMAPTJAK2PIM1 | |
| SCHEMBL20190041 | 0.87 | GSK3B (0.69) | GSK3BGSK3AMAPTJAK2PIM1 | |
| SCHEMBL20205182 | 0.83 | GSK3A (0.64) | GSK3BGSK3AMAPTJAK2PIM1 | |
| SCHEMBL29939514 | 0.83 | GSK3A (0.64) | GSK3BGSK3AMAPTJAK2PIM1 | |
| SCHEMBL29939539 | 0.80 | GSK3A (0.74) | GSK3BGSK3AMAPTJAK2PIM1 | |
| SCHEMBL20205102 | 0.80 | GSK3A (0.74) | GSK3BGSK3AMAPTJAK2PIM1 | |
| SCHEMBL20204943 | 0.79 | GSK3A (0.69) | GSK3BGSK3AMAPTJAK2PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3544613-B1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-09 | — | — | EP | disclosed |
| WO-2018098412-A1 | GSK-3 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-31 | — | — | WO | disclosed |